Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$693M |
| 2 |
Constellation Brands
STZ
|
+$368M |
| 3 |
Tesla
TSLA
|
+$332M |
| 4 |
NVIDIA
NVDA
|
+$300M |
| 5 |
Booking.com
BKNG
|
+$251M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Charter Communications
CHTR
|
+$821M |
| 2 |
Netflix
NFLX
|
+$777M |
| 3 |
AbbVie
ABBV
|
+$583M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$477M |
| 5 |
FedEx
FDX
|
+$456M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.07% |
| 2 | Consumer Discretionary | 17.72% |
| 3 | Financials | 13.25% |
| 4 | Healthcare | 11.94% |
| 5 | Communication Services | 11.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
426
Agios Pharmaceuticals
AGIO
$2.14B
| $16.3M | 0.02% |
193,935
+3,183
| +2% | +$278K |
|
427
Schneider National
SNDR
$6.34B
| $16.3M | 0.02% |
593,261
-695,218
| -54% | -$19.3M |
|
428
Spyre Therapeutics
SYRE
$8.68B
| $16.1M | 0.02% |
61,018
+814
| +1% | +$200K |
|
|
QTS
429
DELISTED
QTS REALTY TRUST, INC.
QTS
| $16M | 0.02% |
405,346
-160,703
| -28% | -$5.93M |
|
430
Ocular Therapeutix
OCUL
$1.85B
| $15.7M | 0.02% |
2,319,255
+26,503
| +1% | +$182K |
|
431
Coca-Cola
KO
$380B
| $15.6M | 0.02% |
355,626
-203,785
| -36% | -$8.8M |
|
|
SYNH
432
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $15.5M | 0.02% |
330,206
-301,014
| -48% | -$12.5M |
|
433
Acadia Healthcare
ACHC
$3.01B
| $15.4M | 0.02% |
377,446
+16,475
| +5% | +$664K |
|
|
X
434
DELISTED
US Steel
X
| $15.4M | 0.02% |
444,048
-93,516
| -17% | -$3.34M |
|
|
EIGR
435
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $15.3M | 0.01% |
41,883
+20,212
| +93% | +$7.2M |
|
436
Monro
MNRO
$537M
| $15.1M | 0.01% |
+260,269
| New | +$14.7M |
|
437
Alcoa
AA
$11.7B
| $15M | 0.01% |
319,022
-12,865
| -4% | -$647K |
|
438
Chemours
CC
$2.57B
| $14.8M | 0.01% |
334,179
+64,725
| +24% | +$3.22M |
|
|
NBLX
439
DELISTED
Noble Midstream Partners LP
NBLX
| $14.7M | 0.01% |
288,165
-2,488
| -0.9% | -$120K |
|
|
SHPG
440
DELISTED
Shire pic
SHPG
| $14.5M | 0.01% |
85,740
-84,773
| -50% | -$13.7M |
|
|
BPMC
441
DELISTED
Blueprint Medicines
BPMC
| $14M | 0.01% |
220,882
+12,408
| +6% | +$987K |
|
442
Huron Consulting
HURN
$1.97B
| $14M | 0.01% |
342,717
+17,703
| +5% | +$689K |
|
|
MMP
443
DELISTED
Magellan Midstream Partners, L.P.
MMP
| $13.9M | 0.01% |
200,623
+129,331
| +181% | +$8.69M |
|
|
MNDT
444
DELISTED
Mandiant, Inc. Common Stock
MNDT
| $13.7M | 0.01% |
+892,477
| New | +$15.5M |
|
445
Box
BOX
$4.36B
| $13.4M | 0.01% |
536,630
+26,921
| +5% | +$667K |
|
446
Constellium
CSTM
$3.96B
| $13.3M | 0.01% |
1,295,508
-78,153
| -6% | -$908K |
|
447
Cogent Biosciences
COGT
$6.95B
| $13.3M | 0.01% |
233,827
+9,638
| +4% | +$463K |
|
448
Philips
PHG
$24.8B
| $13.3M | 0.01% |
404,331
-6,212
| -2% | -$199K |
|
449
Nutrien
NTR
$33.3B
| $12.8M | 0.01% |
236,080
-12,727
| -5% | -$631K |
|
|
AM
450
DELISTED
ANTERO MIDSTREAM PARTNERS LP
AM
| $12.8M | 0.01% |
434,536
-2,629
| -0.6% | -$74K |
|
Similar funds
Jennison Associates's Q2 2018 Portfolio in Review
As of Q2 2018, Jennison Associates held 740 positions worth $103B, up 2% from $101B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Jennison Associates withdrew a net $3.95B in Q2 2018, closing 87 positions and reducing 296 holdings. Its most notable exit was Great Plains Energy Incorporated, an estimated $152M position sold in full.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 21% a quarter earlier, followed by Consumer Discretionary and Financials.
Against the trend, Jennison Associates opened a new position in AstraZeneca worth $677M.
- Jennison Associates's largest Q2 2018 buy was AstraZeneca: 9,637,084 shares worth $677M.
- Jennison Associates added most to Constellation Brands in Q2 2018, an estimated $368M increase.
- Jennison Associates's biggest Q2 2018 reduction was Charter Communications, cutting an estimated $821M.
- Jennison Associates fully exited Great Plains Energy Incorporated in Q2 2018, selling an estimated $152M.
- Jennison Associates's ten largest holdings make up 29% of its $103B portfolio in Q2 2018.
- Jennison Associates opened 89 new positions and closed 87 in Q2 2018.
- Jennison Associates's portfolio value rose 2% quarter-over-quarter to $103B.
Based on Jennison Associates's 13F filing for Q2 2018, filed 2 Aug 2018.